Ergoteles LLC Aligos Therapeutics, Inc. Transaction History
Ergoteles LLC
- $68.2 Billion
- Q3 2023
Shares
3 transactions
Others Institutions Holding ALGS
# of Institutions
52Shares Held
47.3MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$59.5 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$52.4 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$50 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$41 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$29.1 Million0.18% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $326M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...